Most peptides being sold in the wellness market today have not been through the clinical trials required to prove they produce a meaningful effect in humans. A small number (most notably the GLP-1 class and the next-generation Eli Lilly candidate retatrutide, which delivered up to 16.8% weight loss in its first phase 3 trial) have…
